Top Low Price Stocks To Watch For 2023


If you’re on the hunt for value stocks to buy, you’ve come to the right place.

In an ode to Ben Graham, arguably the father of investing, I’m going to pull together a list of 10 stocks trading below book value that I believe will appreciate over the next 12 to 24 months.

However, it’s not going to be easy.

I came across an online Barron’s article that discussed the difficulty of buying stocks below book value, as Graham did back in his prime.

Michael Green, portfolio manager at Moody Aldrich Partners “notes that just 6% of New York Stock Exchange companies now trade under book value, versus 25% in March 2000, when the major averages peaked (Green excludes closed-end and bond funds in making this calculation.),” Andrew Bary wrote in 2004.

“Cheap stocks actually were more plentiful during the market bubble than they are now, due to the narrow breadth of the technology-led market advance in 1999 and early 2000. Over the past 75 years, low price-book stocks on the Big Board were most abundant at the historic market bottoms of 1932 and 1975.”

Top Low Price Stocks To Watch For 2023: Kirin Holdings Company, Limited (KNBWY)


Kirin Holdings Company, Limited is a holding company. The Company is engaged in alcohol beverages, non-alcohol beverages, and pharmaceuticals and bio-chemicals businesses. The Company’s segments include Integrated Beverages, Pharmaceuticals and Bio-chemicals, and Others. Its Others segment includes food business, such as dairy products, and others. Its businesses comprise Japan Integrated Beverages, Overseas Integrated Beverages, and Pharmaceuticals and Bio-chemicals. The Japan Integrated Beverages business conducts manufacturing and sales of alcoholic beverages and non-alcoholic beverages in Japan. The Overseas Integrated Beverages business includes Lion Nathan Limited (Lion), Schincariol Participacoes e Representacoes S.A. (Brasil Kirin) and Myanmar Brewery Limited. The Pharmaceuticals and Bio-chemicals business includes Kyowa Hakko Kirin Co., Ltd., ProStrakan Group plc and Kyowa Hakko Bio Co., Ltd.
Advisors’ Opinion:

  • [By Logan Wallace]

    Kirin (OTCMKTS:KNBWY) is scheduled to be issuing its quarterly earnings data on Thursday, February 14th.

    Shares of KNBWY stock opened at $23.19 on Tuesday. Kirin has a 12 month low of $19.71 and a 12 month high of $30.08. The company has a current ratio of 1.41, a quick ratio of 1.09 and a debt-to-equity ratio of 0.30. The firm has a market capitalization of $21.23 billion, a price-to-earnings ratio of 15.06 and a beta of 0.56.

Top Low Price Stocks To Watch For 2023: Tekla Healthcare Opportunies Fund(THQ)


Tekla Healthcare Opportunities Fund is a non-diversified closed-end management investment company. The Fund’s investment objective is to seek current income and long-term capital appreciation through investments in the United States and non-United States companies in the healthcare industry, including equity securities, debt securities, and pooled investment vehicles. The Fund invests in securities of public and private companies. The Fund may invest in private companies and other restricted securities, including private investments in public equity and venture capital investments, if these securities would comprise 10% or less of Managed Assets. The Fund’s investment portfolio includes information technology, healthcare, consumer discretionary, telecommunications, industrials, consumer staples, financials, utilities, energy and materials. Tekla Capital Management LLC is the investment adviser to the Fund. Advisors’ Opinion:

  • [By Ethan Ryder]

    Tekla Healthcare Opportunities Fund (NYSE:THQ) declared a monthly dividend on Monday, June 11th, Wall Street Journal reports. Investors of record on Wednesday, June 20th will be paid a dividend of 0.1125 per share on Friday, June 29th. This represents a $1.35 dividend on an annualized basis and a dividend yield of 7.72%. The ex-dividend date of this dividend is Tuesday, June 19th.

Top Low Price Stocks To Watch For 2023: Keryx Biopharmaceuticals, Inc.(KERX)

Keryx Biopharmaceuticals, Inc., incorporated on October 22, 1998, is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company’s product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis. The Company operates through the products segment. Auryxia can bind to phosphate in the gastrointestinal tract and form non-absorbable complexes to reduce intestinal absorption and aid in the management of hyperphosphatemia in patients with CKD. The adverse events for Auryxia treated patients were gastrointestinal-related, including diarrhea, nausea, constipation, vomiting and cough.


The Company focuses on Keryx Patient Plus program to assist with patient accessibility to Auryxia. The Keryx Patient Plus program offers benefit verification, co-pay assistance for eligible commercial patients, a no-cost drug program for those who qualify, and a short-term prescription bridge program that may assist those already on Auryxia who are in danger of suffering a lapse in coverage. The approval of Auryxia was based on data from its Phase III registration program, in which Auryxia effectively reduced serum phosphorus levels to well within the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines range of 3.5 to 5.5 milligrams per deciliter. In addition to the effects on serum phosphorus levels, Auryxia’s pharmacodynamic properties resulted in increased ferritin, iron and transferrin saturation (TSAT), whereas these parameters remained relatively constant in patients treated with active control (Renvela and/or PhosLo).


The Company competes with Sanofi, Fresenius Medical Care and Shire Pharmaceuticals Group plc.

Advisors’ Opinion:

  • [By Shane Hupp]

    ILLEGAL ACTIVITY WARNING: “Bank of New York Mellon Corp Sells 69,607 Shares of Keryx Biopharmaceuticals (KERX)” was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at www.tickerreport.com/banking-finance/4158332/bank-of-new-york-mellon-corp-sells-69607-shares-of-keryx-biopharmaceuticals-kerx.html.

  • [By Logan Wallace]

    Keryx Biopharmaceuticals (NASDAQ:KERX) has been assigned an average rating of “Hold” from the eight brokerages that are covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, five have given a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $6.00.

  • [By Ethan Ryder]

    Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.02). equities research analysts expect that Keryx Biopharmaceuticals will post -0.61 earnings per share for the current fiscal year.

  • [By Maxx Chatsko]

    Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) dropped nearly 20% last month, according to data from S&P Global Market Intelligence. The pharma company announced second-quarter and first-half 2018 results that included disappointing sales revenue for its only drug, Auryxia. As a result, sales lagged behind consensus estimates despite delivering strong year-over-year growth.

Top Low Price Stocks To Watch For 2023: Simmons First National Corporation(SFNC)

Simmons First National Corporation (the “Company”) is a financial holding company registered under the Bank Holding Company Act of 1956, as amended. The Company is headquartered in Arkansas with total assets of $7.6 billion, loans of $4.9 billion, deposits of $6.1 billion and equity capital of $1.1 billion as of December 31, 2015. We conduct banking operations through 149 branches, or “financial centers,” located in communities throughout Arkansas, Kansas, Missouri and Tennessee.


We seek to build shareholder value by (i) focusing on strong asset quality, (ii) maintaining strong capital (iii) managing our liquidity position, (iv) improving our operational efficiency (v) opportunistically growing our business, both organically and through acquisitions of financial institutions.

Subsidiary Bank

Our subsidiary bank, Simmons First National Bank (“Simmons Bank” or “lead bank”), is a national bank which has been in operation since 1903.   Advisors’ Opinion:

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Simmons First National (SFNC)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Allred Capital Management LLC purchased a new position in shares of Simmons First National Co. (NASDAQ:SFNC) in the fourth quarter, HoldingsChannel.com reports. The institutional investor purchased 13,770 shares of the bank’s stock, valued at approximately $332,000.

Leave a Reply

Your email address will not be published.